A Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 After Once-Daily Repeated Oral Doses in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs Orvepitant (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2008 New trial record.